Xynomic Pharmaceuticals is a clinical-stage oncology therapeutics biopharmaceutical company. It focuses on in-licensing, developing, and commercializing oncology pharmaceuticals. The company develops drug candidates against renal cell carcinoma, non-Hodgkin’s lymphoma, and solid tumors.